Headlines about Novartis AG (NYSE:NVS) have been trending positive this week, according to Alpha One. Alpha One, a subsidiary of Accern, rates the sentiment of media coverage by analyzing more than 20 million news and blog sources. Alpha One ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Novartis AG earned a daily sentiment score of 0.32 on Alpha One’s scale. Alpha One also gave headlines about the company an impact score of 87 out of 100, meaning that recent media coverage is very likely to have an impact on the company’s share price in the near future.
Here are some of the news headlines that may have effected Alpha One Sentiment’s rankings:
- Novartis AG (NVS) Rating Reiterated by Morgan Stanley (americanbankingnews.com)
- John G Ullman & Associates Boosted Its Novartis Ag (NVS) Holding; Shorts at Hornbeck Offshore Services (HOS … – UtahHerald.com (utahherald.com)
- Novartis Presents Data on Tafinlar-Mekinist Combination – Nasdaq (nasdaq.com)
- Novartis Collaborates With IBM On Outcomes-based Care In Advanced Breast Cancer (finanznachrichten.de)
- Novartis AG Joins GlaxoSmithKline And Gets Over Its Fear Of Heights (biospace.com)
NVS has been the subject of a number of research analyst reports. Vetr cut Novartis AG from a “hold” rating to a “sell” rating and set a $71.49 target price for the company. in a research note on Monday, February 6th. Liberum Capital initiated coverage on Novartis AG in a research note on Thursday, March 9th. They issued a “buy” rating for the company. JPMorgan Chase & Co. reissued a “neutral” rating on shares of Novartis AG in a research note on Friday. Barclays PLC initiated coverage on Novartis AG in a research note on Tuesday, March 7th. They issued an “underweight” rating for the company. Finally, Goldman Sachs Group Inc reissued a “neutral” rating on shares of Novartis AG in a research note on Wednesday, March 22nd. Three investment analysts have rated the stock with a sell rating, ten have assigned a hold rating and five have issued a buy rating to the company’s stock. Novartis AG has an average rating of “Hold” and an average price target of $83.12.
Novartis AG (NYSE NVS) traded up 0.01% on Tuesday, hitting $81.84. The stock had a trading volume of 1,376,839 shares. The stock has a market capitalization of $193.60 billion, a price-to-earnings ratio of 30.77 and a beta of 0.73. The company has a 50-day moving average price of $78.45 and a 200-day moving average price of $74.50. Novartis AG has a 52 week low of $66.93 and a 52 week high of $83.58.
Novartis AG (NYSE:NVS) last issued its earnings results on Tuesday, April 25th. The company reported $1.13 EPS for the quarter, beating analysts’ consensus estimates of $1.10 by $0.03. Novartis AG had a return on equity of 15.37% and a net margin of 13.80%. The business had revenue of $11.54 billion during the quarter, compared to analyst estimates of $11.59 billion. During the same period in the previous year, the company posted $1.17 EPS. The firm’s revenue was down .5% compared to the same quarter last year. Equities research analysts anticipate that Novartis AG will post $4.70 earnings per share for the current fiscal year.
Novartis AG Company Profile
Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.
This story was originally published by sleekmoney (https://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://sleekmoney.com/positive-news-coverage-very-likely-to-affect-novartis-ag-nvs-stock-price/1885803.html
Receive News & Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related companies with MarketBeat.com's FREE daily email newsletter.